Supernus Pharmaceuticals annual working capital
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Working Capital Growth & History (SUPN)
Supernus Pharmaceuticals's working capital was $306.0M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $306.0M | −$87.7M | −22.27% |
| 2024 | 2024-12-31 | $393.7M | $190.8M | +94.01% |
| 2023 | 2023-12-31 | $202.9M | $156.7M | +339.28% |
| 2022 | 2022-12-31 | $46.2M | −$240.0M | −83.86% |
| 2021 | 2021-12-31 | $286.2M | −$99.1M | −25.72% |
| 2020 | 2020-12-31 | $385.3M | $73.3M | +23.47% |
| 2019 | 2019-12-31 | $312.1M | −$20.1M | −6.04% |
| 2018 | 2018-12-31 | $332.1M | $226.7M | +214.97% |
| 2017 | 2017-12-31 | $105.5M | $34.8M | +49.23% |
| 2016 | 2016-12-31 | $70.7M | $21.6M | +44.17% |
| 2015 | 2015-12-31 | $49.0M | −$31.6M | −39.19% |
| 2014 | 2014-12-31 | $80.6M | $9.8M | +13.91% |
| 2013 | 2013-12-31 | $70.8M | $2.3M | +3.33% |
| 2012 | 2012-12-31 | $68.5M | $37.9M | +123.58% |
| 2011 | 2011-12-31 | $30.6M | — | — |
Supernus Pharmaceuticals quarterly working capital
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $376.1M | −$76.4M | −16.88% |
| Q1 2026 | 2026-03-31 | $357.7M | −$48.2M | −11.87% |
| Q4 2025 | 2025-12-31 | $306.0M | −$87.7M | −22.27% |
| Q3 2025 | 2025-09-30 | $263.3M | −$85.2M | −24.46% |
| Q2 2025 | 2025-06-30 | $452.5M | $170.2M | +60.27% |
| Q1 2025 | 2025-03-31 | $405.8M | $176.0M | +76.62% |
| Q4 2024 | 2024-12-31 | $393.7M | $190.8M | +94.01% |
| Q3 2024 | 2024-09-30 | $348.5M | $186.7M | +115.35% |
| Q2 2024 | 2024-06-30 | $282.3M | $111.4M | +65.16% |
| Q1 2024 | 2024-03-31 | $229.8M | $78.0M | +51.37% |
| Q4 2023 | 2023-12-31 | $202.9M | $156.7M | +339.28% |
| Q3 2023 | 2023-09-30 | $161.8M | $223.9M | — |
| Q2 2023 | 2023-06-30 | $170.9M | $281.4M | — |
| Q1 2023 | 2023-03-31 | $151.8M | −$132.2M | −46.54% |
| Q4 2022 | 2022-12-31 | $46.2M | −$240.0M | −83.86% |
| Q3 2022 | 2022-09-30 | −$62.1M | −$495.8M | — |
| Q2 2022 | 2022-06-30 | −$110.4M | −$466.2M | — |
| Q1 2022 | 2022-03-31 | $284.0M | −$61.3M | −17.74% |
| Q4 2021 | 2021-12-31 | $286.2M | −$99.1M | −25.72% |
| Q3 2021 | 2021-09-30 | $433.7M | $181.3M | +71.81% |
| Q2 2021 | 2021-06-30 | $355.8M | $67.9M | +23.59% |
| Q1 2021 | 2021-03-31 | $345.2M | −$43.5M | −11.19% |
| Q4 2020 | 2020-12-31 | $385.3M | $73.3M | +23.47% |
| Q3 2020 | 2020-09-30 | $252.4M | −$25.0M | −9.00% |
| Q2 2020 | 2020-06-30 | $287.9M | $40.9M | +16.58% |
| Q1 2020 | 2020-03-31 | $388.7M | $120.5M | +44.90% |
| Q4 2019 | 2019-12-31 | $312.1M | −$20.1M | −6.04% |
| Q3 2019 | 2019-09-30 | $277.4M | $25.2M | +9.97% |
| Q2 2019 | 2019-06-30 | $246.9M | $66.4M | +36.75% |
| Q1 2019 | 2019-03-31 | $268.3M | −$195.9M | −42.20% |
| Q4 2018 | 2018-12-31 | $332.1M | $226.7M | +214.97% |
| Q3 2018 | 2018-09-30 | $252.2M | $165.8M | +192.00% |
| Q2 2018 | 2018-06-30 | $180.6M | $100.6M | +125.82% |
| Q1 2018 | 2018-03-31 | $464.2M | $396.4M | +585.06% |
| Q4 2017 | 2017-12-31 | $105.5M | $34.8M | +49.23% |
| Q3 2017 | 2017-09-30 | $86.4M | $19.8M | +29.78% |
| Q2 2017 | 2017-06-30 | $80.0M | $33.3M | +71.51% |
| Q1 2017 | 2017-03-31 | $67.8M | $29.3M | +76.34% |
| Q4 2016 | 2016-12-31 | $70.7M | $21.6M | +44.17% |
| Q3 2016 | 2016-09-30 | $66.6M | $7.7M | +13.14% |
| Q2 2016 | 2016-06-30 | $46.6M | −$22.7M | −32.74% |
| Q1 2016 | 2016-03-31 | $38.4M | −$36.2M | −48.53% |
| Q4 2015 | 2015-12-31 | $49.0M | −$31.6M | −39.19% |
| Q3 2015 | 2015-09-30 | $58.8M | −$22.0M | −27.23% |
| Q2 2015 | 2015-06-30 | $69.3M | $16.5M | +31.31% |
| Q1 2015 | 2015-03-31 | $74.7M | $21.8M | +41.31% |
| Q4 2014 | 2014-12-31 | $80.6M | $9.8M | +13.91% |
| Q3 2014 | 2014-09-30 | $80.8M | — | — |
| Q2 2014 | 2014-06-30 | $52.8M | −$41.8M | −44.19% |
| Q1 2014 | 2014-03-31 | $52.8M | $3.5M | +7.10% |
| Q4 2013 | 2013-12-31 | $70.8M | $2.3M | +3.33% |
| Q2 2013 | 2013-06-30 | $94.6M | $38.7M | +69.15% |
| Q1 2013 | 2013-03-31 | $49.3M | $30.8M | +166.54% |
| Q4 2012 | 2012-12-31 | $68.5M | $37.9M | +123.58% |
| Q3 2012 | 2012-09-30 | $38.3M | — | — |
| Q2 2012 | 2012-06-30 | $55.9M | — | — |
| Q1 2012 | 2012-03-31 | $18.5M | — | — |
| Q4 2011 | 2011-12-31 | $30.6M | — | — |
Supernus Pharmaceuticals working capital trends
Over the last five fiscal years, Supernus Pharmaceuticals's working capital decreased from $385.3M to $306.0M, a change of −$79.3M. The latest reported quarter, Q2 2026, shows $376.1M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
